|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 14377 |
FusionGeneSummary for GART_FCHO2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: GART_FCHO2 | Fusion gene ID: 14377 | Hgene | Tgene | Gene symbol | GART | FCHO2 | Gene ID | 2618 | 115548 |
| Gene name | phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase | FCH domain only 2 | |
| Synonyms | AIRS|GARS|GARTF|PAIS|PGFT|PRGS | - | |
| Cytomap | 21q22.11 | 5q13.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | trifunctional purine biosynthetic protein adenosine-3GAR transformylaseGARS-AIRS-GARTglycinamide ribonucleotide formyltransferaseglycinamide ribonucleotide synthetase-aminoimidazole ribonucleotide synthetase-glycinamide ribonucleotide transformylase | F-BAR domain only protein 2FCH domain only protein 2 | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | P22102 | Q0JRZ9 | |
| Ensembl transtripts involved in fusion gene | ENST00000381815, ENST00000381831, ENST00000381839, ENST00000543717, ENST00000361093, ENST00000497313, | ENST00000341845, ENST00000430046, ENST00000512348, ENST00000287761, | |
| Fusion gene scores | * DoF score | 5 X 5 X 3=75 | 3 X 3 X 1=9 |
| # samples | 5 | 3 | |
| ** MAII score | log2(5/75*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/9*10)=1.73696559416621 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: GART [Title/Abstract] AND FCHO2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BF763230 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000381815 | ENST00000341845 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000381815 | ENST00000430046 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000381815 | ENST00000512348 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-intron | ENST00000381815 | ENST00000287761 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000381831 | ENST00000341845 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000381831 | ENST00000430046 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000381831 | ENST00000512348 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-intron | ENST00000381831 | ENST00000287761 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000381839 | ENST00000341845 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000381839 | ENST00000430046 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000381839 | ENST00000512348 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-intron | ENST00000381839 | ENST00000287761 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000543717 | ENST00000341845 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000543717 | ENST00000430046 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000543717 | ENST00000512348 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-intron | ENST00000543717 | ENST00000287761 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000361093 | ENST00000341845 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000361093 | ENST00000430046 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000361093 | ENST00000512348 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-intron | ENST00000361093 | ENST00000287761 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000497313 | ENST00000341845 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000497313 | ENST00000430046 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-3CDS | ENST00000497313 | ENST00000512348 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
| intron-intron | ENST00000497313 | ENST00000287761 | GART | chr21 | 34887528 | + | FCHO2 | chr5 | 72359704 | + |
Top |
FusionProtFeatures for GART_FCHO2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| GART | FCHO2 |
| Functions in an early step of clathrin-mediatedendocytosis. Has both a membrane binding/bending activity and theability to recruit proteins essential to the formation offunctional clathrin-coated pits. Has a lipid-binding activity witha preference for membranes enriched in phosphatidylserine andphosphoinositides (Pi(4,5) biphosphate) like the plasma membrane.Its membrane-bending activity might be important for thesubsequent action of clathrin and adaptors in the formation ofclathrin-coated vesicles. Involved in adaptor protein complex AP-2-dependent endocytosis of the transferrin receptor, it alsofunctions in the AP-2-independent endocytosis of the LDL receptor.{ECO:0000269|PubMed:17540576, ECO:0000269|PubMed:20448150,ECO:0000269|PubMed:21762413, ECO:0000269|PubMed:22323290}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for GART_FCHO2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for GART_FCHO2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for GART_FCHO2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | GART | P22102 | DB00642 | Pemetrexed | Trifunctional purine biosynthetic protein adenosine-3 | small molecule | approved|investigational |
Top |
RelatedDiseases for GART_FCHO2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | GART | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|